Alteration of Gastric Functions and Candidate Genes Associated With Weight Reduction in Response to Sibutramine
| Autor: | Matthew M. Clark, Michael D. Jensen, Alan R. Zinsmeister, Karen M. Graszer, Maria Vazquez Roque, Debra A. TePoel, Sarah A. Kalsy, Duane Burton, Kari Baxter, Michael Camilleri |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male GABA Plasma Membrane Transport Proteins medicine.medical_specialty Adolescent Genotype Placebo Body Mass Index Double-Blind Method Weight loss Internal medicine Appetite Depressants Weight Loss medicine Humans Obesity Chromatography High Pressure Liquid Aged Retrospective Studies Polymorphism Genetic Hepatology Gastric emptying business.industry Stomach Gastroenterology DNA Organ Size Middle Aged Treatment Outcome medicine.anatomical_structure Endocrinology Postprandial Gastric Emptying Peptide YY Female medicine.symptom Reuptake inhibitor business Cyclobutanes Follow-Up Studies Sibutramine medicine.drug |
| Zdroj: | Clinical Gastroenterology and Hepatology. 5:829-837 |
| ISSN: | 1542-3565 |
| DOI: | 10.1016/j.cgh.2007.02.037 |
| Popis: | It is unclear whether weight loss with the noradrenergic (norepinephrine) and serotonergic (5-hydroxytryptamine) reuptake inhibitor, sibutramine, is associated with altered stomach functions and whether genetics influence treatment response.Forty-eight overweight and obese but otherwise healthy participants were randomized to placebo or sibutramine (15 mg/day for 12 weeks). At baseline and posttreatment we measured the following: gastric emptying for solids and liquids by scintigraphy, gastric volumes by single-photon emission computed tomography, maximum tolerated volume and 30-minute postnutrient challenge symptoms, and selected gastrointestinal hormones. All participants received structured behavior therapy for weight management. The influence of candidate gene polymorphisms involved in norepinephrine and 5-hydroxytryptamine or receptor function (phenylethanolamine N-methyltransferase, guanine nucleotide binding protein beta polypeptide 3, alpha2A adrenoreceptor, and solute carrier family 6 [neurotransmitter transporter, serotonin] member 4 [homo sapiens] [SLC6A4]) on weight loss and gastric functions was evaluated.The overall average weight loss posttreatment was 5.4 +/- 0.8 (SEM) kg with sibutramine and 0.9 +/- 0.9 kg with placebo (P.001). The sibutramine group showed significant retardation in gastric emptying of solids (P = .03), reduced maximum tolerated volume (P = .03), and increased postprandial peptide YY compared with the placebo group. Obese females showed greater effects of sibutramine on weight loss and gastric emptying of solids and liquids. Gastric volumes and postchallenge symptoms were not significantly different in the 2 treatment groups. The LS/SS genotype of the promoter for SLC6A4 was associated with enhanced weight loss with sibutramine.Weight reduction with sibutramine is associated with altered gastric functions and increased peptide YY and is significantly associated with SLC6A4 genotype. The role of genetic variation in SLC6A4 on weight loss in response to sibutramine deserves further study. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|